Melanoma surveillance in the United States: Overview?of methods

详细信息    查看全文

• 作者：Meg  ; Watson MPH^a ;   ; ^{MWatson2@cdc.gov} ; Christopher J.  ; Johnson MPH^b ; Vivien W.  ; Chen PhD^c ; Cheryll C.  ; Thomas MSPH^a ; Hannah K.  ; Weir PhD^a ; Recinda  ; Sherman MPH^d ; Myles  ; Cockburn PhD^e ; Jeannette  ; Jackson-Thompson MSPH ; PhD^f ; Mona  ; Saraiya MD ; MPH^a
• 关键词：cancer ; epidemiology ; melanoma ; methods ; public health ; surveillance
• 刊名：Journal of the American Academy of Dermatology
• 出版年：2011
• 出版时间：November 2011
• 年：2011
• 卷：65
• 期：5_supp_S1
• 页码：S6-S16
• 全文大小：848 K

文摘

g=""UTF-8""?>

Background

Skin cancer is the most common form of cancer in the United States. Melanoma skin cancer is particularly deadly; more than 8000 US residents die from it each year. Although recent reports suggest that melanoma incidence rates have been increasing, these apparent increases could be caused by an increase in reporting and/or screening, and by an actual increase in the occurrence of melanoma.

Objective

In this report, we describe methods used in this supplement to assess the current burden of melanoma in the United States using data from two federal cancer surveillance programs: the Centers for Disease Control and Prevention (CDC) National Program of Cancer Registries and the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results program. We also provide basic descriptive epidemiologic data about melanoma in the United States.

Methods

Cancer incidence data from population-based cancer registries that participate in the CDC National Program of Cancer Registries and/or the NCI Surveillance, Epidemiology, and End Results Program covering 78 % of the US population for 2004 to 2006 were used.

Results

Over 45 thousand melanomas were diagnosed annually, with a rate of 19 cases per 100,000 persons.

Limitations

Melanoma rates may vary because of differences in reporting, diagnosis, and screening.

Conclusion

To our knowledge, the articles in this supplement constitute the first comprehensive examination of the overall burden of melanoma in the United States based on data from a majority of the US population.